Recently, AI pharmaceutical R&D solution provider Beijing Deepin Manufacturing Technology Co., Ltd. completed Series D financing of nearly 50 million US dollars. This round was led by Dinghui Investment, followed by Xinding Capital and Sequoia China. The funds will be used to accelerate the technological iteration of agent clusters and the expansion of global pharmaceutical company cooperation. Established in 2018, Deepin Zhiyao focuses on providing full-stack intelligent solutions for pharmaceutical companies from pre-clinical to post-marketing. The company was previously invested by a well-known Chinese institution from Sequoia.

Recently, AI pharmaceutical R&D solution provider Beijing Deepin Manufacturing Technology Co., Ltd. completed Series D financing of nearly 50 million US dollars. This round was led by Dinghui Investment, followed by Xinding Capital and Sequoia China. The funds will be used to accelerate the technological iteration of agent clusters and the expansion of global pharmaceutical company cooperation. Established in 2018, Deepin Zhiyao focuses on providing full-stack intelligent solutions for pharmaceutical companies from pre-clinical to post-marketing. The company was previously invested by a well-known Chinese institution from Sequoia.